Loading
A phase 1/2 trial of LBL-024 for Injection in advanced solid tumours, run by Nanjing Leads Biolabs Co.,Ltd, now recruiting.
A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05170958 by Nanjing Leads Biolabs Co.,Ltd, with 396 participants planned, started 2022-01-06 and due to reach its primary completion in 2026-12. Interventions recorded: LBL-024 for Injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Nanjing Leads Biolabs and the tag pipeline.
Shares Nanjing Leads Biolabs, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/